CASTLE BIOSCIENCES INC (CSTL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CSTL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CSTL | Founder and President; Class I Director | 52 | ["Founder and President of CHORD Consulting","Previously served as Vice President of Marketing at Crescendo Biosciences","Led marketing at Genomic Health","Holds a B.S. degree in chemistry from Yale University","Holds a M.S. in chemistry and an MBA from Stanford University","Commercial Execution Experience","Life Science Industry Experience","Digital Health","Regulatory/ Lab Services Reimbursement","Diversity of Skills, Background, and Perspective","Founder and President of CHORD Consulting since 2011","Vice President of Marketing at Crescendo Bioscience","Strategy consultant with Booz Allen & Hamilton","Developed new products at ALZA Corporation","M.S in Chemistry and MBA from Stanford University","B.S. in Chemistry from Yale University","Fellow of the Aspen Institute’s Health Innovators Fellowship Program","Financial Analysis & Control Experience","Regulatory/Lab Services Reimbursement"] | ["Comp. Committee (Chair)","Nominating and Corporate Governance Committee","Compensation Committee (Chair)"] | 2026 |
Biography sourced from the proxy statement filing.
She has served as a member of our board of directors since July 2021. Ms. Goldberg has served as the Founder and President of CHORD Consulting since 2011, where she works with executives of innovative diagnostics companies to develop and commercialize novel products. She has focused her career on ground-breaking technologies in life-threatening and life-altering diseases. Ms. Goldberg served as Vice President of Marketing at Crescendo Bioscience, developer of Vectra DA , a multi-biomarker blood test that predicts joint damage and enables treatment changes to improve outcomes in rheumatoid arthritis. Prior to Crescendo, Ms. Goldberg led marketing at Genomic Health, where she launched the Oncotype DX Breast Cancer Assay, which went from inception to >$108MM in annual revenue during her tenure, and directed the commercial side of product development for tests in colon cancer, prostate cancer and ductal carcinoma in situ. Ms. Goldberg began her career as a strategy consultant with Booz Allen & Hamilton and developed new products at ALZA Corporation. She has an M.S in Chemistry and an MBA from Stanford University and a B.S. in Chemistry from Yale University. Ms. Goldberg is also a fellow of the Aspen Institute s Health Innovators Fellowship Program. Independent Director Age: 52 Director since: 2021 Committees: Compensation Committee (Chair) Nominating and Corporate Governance Committee Our Nominating and Corporate Governance Committee and board of directors believe Ms. Goldberg s expertise in the development and commercialization of diagnostic tests and commercial leadership experience in the diagnostics qualify her to serve on our board of directors.